FindTrial
Sign In

The impact of different management strategies for patent ductus arteriosus (PDA) in premature infants on clinical outcomes.

The impact of different management strategies for patent ductus arteriosus (PDA) in premature infants on clinical outcomes.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104566
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent ductus arteriosus

Interventions

Conservative therapy:None
Pharmacotherapy:None
Surgical Treatment:None

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 0.1 Years

Inclusion criteria

Inclusion criteria: (1) GA <= 28 weeks and/or BW <= 1.25 kg; (2) Complete clinical data and a clear diagnosis.

Exclusion criteria

Exclusion criteria: (1) Other severe complications of preterm birth are likely to lead to poor prognosis; (2) Severe congenital heart defects (except PDA or patent foramen ovale); (3) Life-threatening congenital or genetic defects; (4) Congenital abnormalities associated with abnormal neurodevelopmental outcomes.

Design outcomes

Primary

MeasureTime frame
Closure status of the patent ductus arteriosus;Bronchopulmonary dysplasia;—

Secondary

MeasureTime frame
Mortality;Hospitalization days;Adverse effects;—

Countries

China

Contacts

Public ContactWang Jianhui

Children's Hospital of Chongqing Medical University

wangjh805@126.com+86 136 7842 8167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026